Over the last 50 years, revascularization and pharmacotherapeutic innovations have led to significant reductions in major adverse CV events associated with both acute and chronic coronary diseases. In historic acute MI trials, long-term use of beta-blockers has led to large reductions in major adverse CV events (MACE). These trials laid the foundation for the widespread and often lifelong use of